Open Access Policy Deposits

Parent: Department of Molecular and Medical Pharmacology

eScholarship stats: History by Item for May through August, 2026

Item	Title	Total requests	2026-08	2026-07	2026-06	2026-05
3rh986fd	Macrophage COX2 Mediates Efferocytosis, Resolution Reprogramming, and Intestinal Epithelial Repair	1,053	464	218	300	71
0290023m	B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer	639	64	114	120	341
4450x915	Targeting PEA3 transcription factors to mitigate small cell lung cancer progression	637	29	18	32	558
4sk065dz	Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial	635	106	123	245	161
19k5q59f	The pentose phosphate pathway in health and disease	624	332	79	122	91
4xj2w70k	Chapter Five Advances in PET Detection of the Antitumor T Cell Response	573	146	119	150	158
54c114pc	Multivalent N‑Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing	538	176	100	129	133
47h17394	PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0	472	292	78	71	31
837669fc	Individual islet respirometry reveals functional diversity within the islet population of mice and human donors	432	57	69	146	160
7jm3422h	PD-1 blockade induces responses by inhibiting adaptive immune resistance	424	130	94	110	90
9623t7mm	Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence	422	74	72	115	161
1zv2z6bg	RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults	409	106	75	84	144
9292w8n6	Multiple early factors anticipate post-acute COVID-19 sequelae	408	250	41	50	67
61s0k68s	Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma	397	94	67	90	146
87s8b0ff	Isolation of Mitochondria from Mouse Tissues for Functional Analysis	390	104	54	96	136
5gr4m7rp	Mammary duct luminal epithelium controls adipocyte thermogenic programme	368	46	65	110	147
5nv9f110	Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression	358	88	85	103	82
0cj1q8m0	Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations	357	93	44	107	113
69s4b6hb	Osteopontin as a Biomarker in Chronic Kidney Disease	355	188	45	64	58
5xq2c221	Metabolic programs of T cell tissue residency empower tumour immunity	341	85	67	85	104
2v0702dq	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma	332	36	63	93	140
9br8v18z	Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients	324	119	56	68	81
7rq9k34t	Vaccine adjuvants: current status, research and development, licensing, and future opportunities	322	51	49	78	144
0f01h1g6	TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination	318	59	50	84	125
1n83k1hm	The “cancer immunogram”	314	91	73	58	92
87x612c2	Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma	314	95	63	69	87
5mp7824g	Immunoresponsive Gene 1 and Itaconate Inhibit Succinate Dehydrogenase to Modulate Intracellular Succinate Levels*	311	113	75	52	71
0zv4p7dc	Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions	309	42	48	92	127
10s8335f	Gynecologic tumor board: a radiologist’s guide to vulvar and vaginal malignancies	305	95	69	69	72
7w98t225	Etomoxir Inhibits Macrophage Polarization by Disrupting CoA Homeostasis	304	128	31	62	83
0bh4n1vq	Targeted agents and immunotherapies: optimizing outcomes in melanoma	301	98	68	62	73
2r15x44h	Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)	298	157	44	31	66
4zw2v599	CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer	297	90	49	84	74
1387q04m	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma	293	97	21	60	115
6t49338z	The whole-genome landscape of medulloblastoma subtypes	291	57	45	77	112
7k76k99h	Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival	291	112	33	74	72
46k649vw	Mitochondria Bound to Lipid Droplets Have Unique Bioenergetics, Composition, and Dynamics that Support Lipid Droplet Expansion	288	77	52	111	48
0g72g9bm	Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.	281	62	46	82	91
6v3011pd	Cancer immunotherapy using checkpoint blockade	279	53	52	92	82
4jr8j2cx	UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas	276	46	58	61	111
0cj235rr	Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma	271	63	51	77	80
5pj4p43b	Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method	271	49	53	71	98
4z6394j3	Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing	270	187	37	23	23
8094s6nw	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction	270	109	48	58	55
5f52f92h	Antitumor Immune Responses in B2M-Deficient Cancers	267	46	70	43	108
342329sk	Context-dependent regulation of ferroptosis sensitivity	264	79	70	54	61
2g96s8v7	Non-viral precision T cell receptor replacement for personalized cell therapy	260	48	39	87	86
5673156t	The Ca2+ sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum	256	68	20	70	98
0t4090cx	Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer	255	68	28	88	71
0fq0574t	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial	252	73	40	52	87

Top

Note: Due to the evolving nature of web traffic, the data presented here should be considered approximate and subject to revision. Learn more.